AMGN 10-K Annual Reports

Amgen Inc. (AMGN) reported strong financial performance for the fiscal year ending December 31, 2025, with total product sales increasing by 10% to $35.1 billion. This growth was primarily driven by a 13% increase in volume, bolstered by key products such as Repatha, EVENITY, TEZSPIRE, and BLINCYTO. The company also saw significant progress in its pipeline, with multiple regulatory approvals and advancements in Phase 3 clinical studies. Amgen's strategic investments in manufacturing capacity expansion and R&D continue to support its long-term growth objectives. However, the company faces ongoing risks from patent expirations, increasing biosimilar competition, and evolving pricing and reimbursement pressures from government and commercial payers.

Amgen Inc. reported robust total revenue growth of 19% for the fiscal year 2024, reaching $33.42 billion. This growth was primarily driven by a 23% increase in product sales volume, boosted significantly by the acquisition of Horizon Therapeutics, which contributed $4.2 billion to sales. Key products like Repatha and TEZSPIRE showed strong performance, with sales increasing by 36% and 71% respectively. However, established products like ENBREL experienced a 10% decline in sales, reflecting ongoing competitive pressures and net selling price decreases. Amgen continued its strategic investment in R&D, with expenses increasing by 25% to $5.96 billion, indicating a strong commitment to pipeline development. The company also focused on debt reduction and returning capital to shareholders, with a 6% increase in its quarterly dividend.

Amgen Inc. reported strong performance in its 2023 Annual Report, highlighted by a significant increase in total product sales, primarily driven by volume growth in key products like Repatha, TEZSPIRE, EVENITY, Prolia, and BLINCYTO. The acquisition of Horizon Therapeutics plc in October 2023 for $27.8 billion was a major strategic move, bolstering Amgen's rare disease portfolio with the addition of TEPEZZA, KRYSTEXXA, and UPLIZNA. Despite a decline in sales for certain established products like ENBREL and Neulasta due to increased competition and pricing pressures, Amgen's overall revenue grew. The company is actively managing its pipeline, with promising developments in its Phase 3 programs and an increased focus on human genetics and innovative technologies. Amgen also continues its commitment to returning capital to shareholders through dividends and share repurchases, while navigating a complex regulatory and reimbursement landscape, including the ongoing tax dispute with the IRS.

Amgen Inc. (AMGN) presented its 2022 annual report, highlighting robust product sales growth, particularly driven by Prolia, Repatha, and EVENITY. The company's total product sales increased by 2% to $24.8 billion, despite challenges like biosimilar competition and pricing pressures. A significant strategic move during the year was the announcement of the proposed acquisition of Horizon Therapeutics for approximately $27.8 billion, signaling Amgen's intent to expand its portfolio into rare, autoimmune, and inflammatory diseases. The company also advanced its pipeline, initiating Phase 3 trials for several key programs, including LUMAKRAS/LUMYKRAS for colorectal cancer and olpasiran for cardiovascular disease. Amgen continues to focus on innovation, manufacturing advancements, and global expansion, while navigating a complex regulatory and reimbursement landscape. The company maintained a strong financial position, with significant cash flow from operations and ongoing capital returns to shareholders through dividends and stock repurchases, though it also faces ongoing litigation regarding tax matters with the IRS.

Amgen Inc.'s 2021 10-K filing highlights a year of strategic advancements and sustained performance despite a challenging global environment marked by the COVID-19 pandemic. The company focused on expanding its product portfolio through key acquisitions, including Five Prime Therapeutics for oncology therapies and Teneobio for its novel biologic technology, alongside significant collaborations. Product sales remained relatively flat year-over-year, with growth in international markets offsetting a slight decline in the U.S., largely due to lower net selling prices and increased competition from biosimilars and generics impacting established products like Enbrel and Neulasta. Amgen demonstrated a commitment to innovation and long-term growth by increasing R&D spending and advancing its pipeline, with notable regulatory approvals for LUMAKRAS and TEZSPIRE. The company also maintained a strong financial position, generating substantial operating cash flow, increasing its dividend, and continuing its share repurchase program. Strategic investments in manufacturing capacity were made to support future demand, underscoring Amgen's focus on operational excellence and reliable supply chains. While facing pricing pressures and ongoing competition, Amgen's diversified portfolio and strategic investments position it for continued resilience and future value creation.

Amgen Inc. reported strong revenue growth in 2020, with total revenues reaching $25.42 billion, a 9% increase driven primarily by the Otezla acquisition and volume growth in key products like Repatha and KYprolis. Despite an overall increase in operating expenses due to Otezla-related costs, the company managed its R&D and SG&A expenses effectively. Amgen also demonstrated its commitment to shareholder returns by increasing its quarterly dividend by 10% and continuing its stock repurchase program. The company is strategically focused on key therapeutic areas including inflammation, oncology/hematology, and cardiovascular disease. Significant pipeline advancements were noted, particularly with the positive results from sotorasib and tezepelumab clinical trials, positioning Amgen for future growth. The company also expanded its global presence through strategic collaborations, such as the investment in BeiGene for the Chinese market, and by establishing a wholly-owned affiliate in Japan. Amgen continues to navigate the challenges of the COVID-19 pandemic, maintaining supply chain stability and adapting its clinical trial operations.

Amgen Inc. (AMGN) filed its Annual Report (Form 10-K) for the fiscal year ended December 31, 2019. This filing's primary purpose was to include the conformed signature of its independent auditor, Ernst & Young LLP, which was inadvertently omitted from the original filing. Therefore, this amended filing does not contain new financial information or reflect events occurring after the original filing date of February 12, 2020. Investors should refer to the original Form 10-K for comprehensive financial details. The audit report from Ernst & Young LLP expresses an unqualified opinion on Amgen's consolidated financial statements for the years ended December 31, 2019 and 2018, and its internal control over financial reporting as of December 31, 2019. Two critical audit matters were highlighted: the estimation of sales deductions and the accounting for unrecognized tax benefits, both involving significant management judgment and complexity.

Amgen Inc.'s 2019 Form 10-K highlights a dynamic year characterized by strategic acquisitions, pipeline advancements, and ongoing efforts to navigate a competitive biopharmaceutical landscape. The company completed the significant acquisition of Otezla®, strengthening its inflammation portfolio, and entered into a major collaboration with BeiGene Ltd. to expand its oncology presence in China. Amgen continued to advance key pipeline candidates, including AMG 510 for non-small cell lung cancer, and saw regulatory approvals and submissions for several products like Kanjinti, Mvasi, Avysol, and Evenity. Despite a slight overall decrease in total product sales due to pricing pressures and biosimilar competition impacting legacy products like Neulasta and Sensipar, Amgen demonstrated resilience with growth in other key areas such as Prolia and Xgeva, and robust cash flow generation that supported significant shareholder returns through dividends and share repurchases. The company's financial performance in 2019 reflected these strategic moves, with R&D expenses increasing to support pipeline development, particularly in oncology. Amgen's focus on innovation, human genetics, and next-generation manufacturing positions it to address unmet medical needs. However, the report also underscores significant risks, including intense competition from biosimilars and generics, pricing and reimbursement pressures from payers, potential regulatory changes, and ongoing patent litigation, all of which could impact future financial performance. The company maintains a strong balance sheet and liquidity, enabling continued investment in R&D and strategic growth initiatives.

Amgen Inc. reported strong financial performance in its 2018 10-K filing, with total revenues reaching $23.7 billion and net income of $8.4 billion. The company saw growth driven by key products like Prolia®, XGEVA®, Repatha®, and KYPROLIS®, alongside successful launches of new medicines such as Aimovig® and Parsabiv®. Amgen continues to invest heavily in research and development, with $3.7 billion spent in 2018, focusing on innovative therapies for serious illnesses and leveraging advancements in human genetics. The company is also actively managing its product portfolio by expanding indications for existing drugs and developing biosimilar versions of key biologics. Challenges include increasing competition from biosimilars and generics, pricing pressures from payers, and ongoing patent litigations, which are carefully monitored and managed.

Amgen Inc. (AMGN) reported stable total revenues for the fiscal year 2017, nearly matching the previous year's performance at $22.85 billion. The company saw strong growth in key products like Prolia and XGEVA, but faced a notable decline in Enbrel and Epogen sales, largely due to increased competition and patent expirations. Despite a 74% decrease in net income, primarily driven by a significant $6.1 billion charge related to the 2017 U.S. Tax Act, Amgen demonstrated resilience with an 8% increase in operating cash flow to $11.2 billion. The company continued its strategic focus on advancing its robust pipeline across six therapeutic areas, including significant developments in neuroscience with Aimovig™ and cardiovascular health with Repatha®. Amgen also actively returned capital to shareholders through dividends and substantial share repurchases, signaling confidence in its long-term financial health and strategic direction. The company is well-positioned for future growth with a strong cash position and ongoing investments in research and development.

Amgen Inc.'s 2016 10-K filing highlights a year of robust growth, with total revenues increasing by 6% to $22.99 billion and net income rising by 11% to $7.72 billion. This performance was driven by strong execution across its therapeutic areas, particularly in bone health, cardiovascular, and oncology, supported by solid net selling prices in the U.S. market. The company made significant strides in advancing its pipeline, with key developments including regulatory filings for EVENITY™ for osteoporosis and positive Phase 3 trial results for Repatha® in cardiovascular outcomes. Amgen also continued its strategic expansion into new global markets and invested in next-generation biomanufacturing. Despite a strong year, Amgen anticipates increased competition and pricing pressures in 2017, particularly from biosimilars, alongside ongoing regulatory scrutiny and evolving healthcare cost containment measures.

Amgen Inc.'s 2015 10-K report highlights a year of strong financial performance, characterized by an 8% increase in total revenues, reaching $21.7 billion, and a significant 35% rise in net income and diluted EPS. This growth was driven by a diverse product portfolio, with notable performance from Enbrel, Neulasta, Sensipar/Mimpara, XGEVA, and Prolia. The company continued its strategic focus on innovation, advancing its pipeline with six new product launches, including in oncology and cardiovascular disease, and making significant progress on key pipeline candidates like Parsabiv, Romosozumab, and Repatha. The report also emphasizes Amgen's commitment to transforming its operations for greater efficiency and reinvesting capital into R&D and shareholder returns through dividends and stock repurchases. However, the company faces increasing competition, particularly from biosimilars, and acknowledges the impact of patent expirations on key products like Neulasta and Epogen. Management expresses confidence in the company's long-term prospects, driven by ongoing R&D, new product launches, and strategic business development, while also acknowledging the persistent challenges of pricing pressures and regulatory environments.

Amgen Inc. reported strong financial performance for the fiscal year ended December 31, 2014, with total revenues reaching $20.06 billion, a 7% increase year-over-year. This growth was primarily driven by robust product sales, particularly in international markets, and the inclusion of Kyprolis® sales following the Onyx acquisition. The company demonstrated a commitment to returning capital to shareholders through increased dividends and ongoing stock repurchase programs. Significant pipeline advancements were made in 2014, with several key product candidates progressing through late-stage clinical trials and regulatory submissions. Notably, Repatha™ (evolocumab) for high cholesterol and BLINCYTO™ for acute lymphoblastic leukemia showed promising developments, with BLINCYTO™ receiving FDA accelerated approval in December 2014. Amgen is also strategically investing in next-generation biomanufacturing and has initiated a restructuring plan to optimize its cost structure and reallocate resources towards innovation and new product launches. However, the company faces increasing competition from biosimilars and anticipates patent expirations for key products, which will require continued focus on R&D and strategic pipeline management.

Amgen Inc. reported robust performance for the fiscal year 2013, characterized by strong revenue growth driven by key products and strategic acquisitions. The acquisition of Onyx Pharmaceuticals in October 2013 significantly expanded Amgen's oncology portfolio, notably with the addition of Kyprolis®. The company highlighted positive clinical trial results for promising pipeline candidates like evolocumab (AMG 145) for dyslipidemia and talimogene laherparepvec for melanoma, indicating a healthy future growth outlook. Despite facing increasing competition and patent expirations for some established products, Amgen maintained a strong financial position and continued its commitment to returning capital to shareholders through dividends and share repurchases. The company navigated a complex regulatory and reimbursement landscape, demonstrating resilience and strategic focus on innovation and market expansion.

This filing is an amendment (10-K/A) to Amgen Inc.'s previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The amendment specifically pertains to Exhibit 10.54, a Collaboration and License Agreement between Amgen and Celltech R&D Limited. The company sought confidential treatment for portions of this exhibit and is refiling it with reduced redactions following discussions with the SEC staff. This amendment does not alter other financial information or disclosures from the original 10-K and is primarily administrative in nature, re-establishing the exhibit with revised confidentiality status.

Amgen Inc. reported robust revenue growth of 11% for the fiscal year 2012, reaching $17.265 billion. This growth was primarily driven by strong performance across its key products, including Neulasta®, Enbrel®, XGEVA®, and Prolia®, which saw significant increases in sales. The company also continued its commitment to returning capital to shareholders through a substantial stock repurchase program and an increased quarterly dividend. Amgen made significant progress in its R&D pipeline, advancing several promising candidates, such as AMG 145, brodalumab, romosozumab, and rilotumumab, into Phase 3 clinical trials. However, the company faces challenges including upcoming patent expirations for key products like NEUPOGEN® and Aranesp®, which are expected to increase competition from biosimilars. Additionally, evolving reimbursement landscapes and ongoing regulatory scrutiny, particularly concerning Enbrel® and its erythropoiesis-stimulating agents (ESAs), present potential headwinds.

Amgen Inc. reported strong performance in its 2011 fiscal year, with total revenues reaching $15.58 billion, a 4% increase from the previous year, driven by robust sales of its key products like Neulasta®/NEUPOGEN®, Enbrel®, and other growing products such as Prolia® and XGEVA®. The company demonstrated a strong commitment to shareholder returns, initiating its first-ever quarterly cash dividends in 2011 and repurchasing approximately 15% of its outstanding stock for $8.3 billion. Amgen also made strategic acquisitions, including BioVex Group and Laboratório Químico Farmacêutico Bérgamo Ltda, to expand its pipeline and market reach. However, the company recorded a significant $780 million charge related to an agreement in principle to settle allegations concerning its sales and marketing practices. Looking ahead, Amgen faced ongoing challenges including increasing competition from biosimilars, patent expirations on key products, and evolving regulatory and reimbursement landscapes. Despite these headwinds, the company expressed confidence in its future growth opportunities driven by its late-stage pipeline and strategic business development initiatives.

Amgen Inc. reported solid performance in its 2010 10-K filing, with total revenues reaching $15.05 billion, a 3% increase from the previous year. The company's principal products—Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, and Enbrel®—continued to be the primary revenue drivers, collectively accounting for approximately 91% of sales in 2010. A significant development highlighted is the launch of Prolia® and XGEVA™ in 2010, representing new growth opportunities. However, Amgen faces ongoing challenges, particularly concerning its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®, due to increased regulatory scrutiny, revised product labeling, and changes in reimbursement policies like the Medicare bundled payment system for dialysis. The company also faces increasing competition from biosimilars in Europe and anticipates similar pressures in the U.S. following the introduction of biosimilar pathways. Amgen remains focused on expanding its pipeline and managing its operational costs effectively amidst these evolving market dynamics.

Amgen Inc. reported strong financial results for the fiscal year ended December 31, 2009, demonstrating resilience despite a challenging market environment. The company's primary products, including Aranesp®, EPOGEN®, Neulasta®, NEUPOGEN®, and Enbrel®, continued to drive significant revenue, although Aranesp® sales experienced a notable decline, primarily attributed to updated product labeling related to safety concerns. Despite this, Amgen maintained a robust balance sheet with substantial cash, cash equivalents, and marketable securities, indicating financial strength and flexibility. The company is actively managing its product pipeline, with significant developments expected from its late-stage product candidate, denosumab, which is under regulatory review and has shown promising clinical trial results. Amgen is also navigating a complex regulatory and reimbursement landscape, particularly concerning its erythropoiesis-stimulating agent (ESA) products, which are subject to ongoing scrutiny and potential label changes. Looking ahead, Amgen faces ongoing challenges related to evolving healthcare reforms, increased competition, and regulatory pressures. However, the company's strategic focus on innovation, coupled with its strong financial position, positions it to continue its mission of delivering innovative therapies to patients facing grievous illnesses.

Amgen Inc. reported total revenues of $15.0 billion for the fiscal year ended December 31, 2008, representing a 3% increase over the prior year. Net income was $4.2 billion, or $3.90 per diluted share. The company faced significant headwinds, particularly from regulatory and reimbursement developments affecting its erythropoiesis-stimulating agent (ESA) products, including Aranesp® and EPOGEN®. These challenges led to a material adverse impact on Aranesp® sales, especially in the U.S. supportive cancer care setting, and also affected EPOGEN® sales due to revised reimbursement policies. Despite these challenges, Amgen demonstrated resilience with strong sales growth in ENBREL® and Neulasta®/NEUPOGEN®. The company also made progress in its late-stage product candidate pipeline, notably with denosumab, for which a biologics license application was submitted to the FDA in December 2008. Amgen continued to manage its cost structure through restructuring initiatives, incurring $887 million in charges through December 31, 2008, with remaining estimated costs to be incurred in 2009.

Amgen Inc.'s 2007 10-K filing highlights a challenging year dominated by significant regulatory and reimbursement headwinds impacting its erythropoiesis-stimulating agent (ESA) products, Aranesp® and EPOGEN®. These challenges, stemming from observed adverse safety results in various studies and subsequent label updates and coverage restrictions by regulatory bodies like the FDA and CMS, led to a substantial reduction in ESA revenues, particularly Aranesp® sales in the U.S. supportive cancer care segment. In response, Amgen initiated a significant restructuring plan, involving staff reductions and operational rationalization, expecting charges of $775 million to $825 million. Despite these setbacks, Amgen reported notable accomplishments, including a successful defense of its intellectual property related to erythropoietin patents against Roche and continued advancement of its pipeline, with positive developments in its denosumab and Nplate™ programs. Strategic collaborations and acquisitions, such as those with Daiichi Sankyo and Takeda, as well as the acquisitions of Alantos and Ilypsa, underscore Amgen's commitment to expanding its R&D capabilities and product pipeline. The company's overall revenues saw a modest increase, driven by strong performance in ENBREL and Neulasta®, though this was substantially offset by the decline in Aranesp® sales. Investors should closely monitor the ongoing impact of regulatory changes, reimbursement policies, and pipeline progress for Amgen's future performance.

Amgen Inc.'s 2006 10-K filing highlights a year of significant growth, driven by strong performance in its core therapeutic areas: supportive cancer care, nephrology, and inflammation. The company's principal products, including Aranesp®, Neulasta®, NEUPOGEN®, EPOGEN®, and Enbrel®, continued to generate substantial revenue, contributing 97% of total product sales in 2006. The launch of Vectibix™ in late 2006 marked an expansion into the oncology market. The company reported significant investments in research and development, with R&D expenses increasing by 45% to support its expanding pipeline and late-stage clinical trials. Amgen also completed strategic acquisitions of Abgenix, Inc. and Avidia, Inc. to enhance its capabilities in monoclonal antibodies and novel protein therapeutics, respectively. Despite strong product sales, Amgen faces increasing competition and regulatory scrutiny, particularly concerning reimbursement policies and potential biosimilar products in international markets.

Amgen Inc. reported strong financial performance for the fiscal year ending December 31, 2005, with total revenues reaching $12.43 billion and net income of $3.67 billion. The company's growth was primarily driven by its key products: Aranesp®, Enbrel®, and Neulasta®. Amgen continues to invest heavily in research and development, with plans for a significant increase in R&D expenses in 2006 to support its expanding pipeline, particularly for the osteoporosis drug denosumab. The company also announced its intent to acquire Abgenix, Inc. for approximately $2.2 billion, which would further bolster its pipeline with the co-developed drug panitumumab. While the company experienced robust sales growth, it also faces increasing competition, particularly from biosimilar products in Europe, and potential impacts from changes in reimbursement policies, notably the Medicare Modernization Act. Amgen is actively managing its manufacturing capacity and supply chain to meet demand and mitigate risks. The company also continued its share repurchase program, returning significant capital to shareholders.

Amgen Inc. reported strong performance in its 2004 annual filing, showcasing significant revenue growth driven by its key therapeutic products. The company's strategic focus on nephrology, supportive cancer care, and inflammatory diseases, supported by blockbuster drugs like EPOGEN®, Aranesp®, Neulasta®, NEUPOGEN®, and ENBREL®, continued to yield substantial sales. The filing highlighted key product developments, including expanded indications and new formulations for ENBREL® and Aranesp®, alongside the introduction of Sensipar® and Kepivancetm. Financially, Amgen demonstrated robust revenue growth, with total revenues reaching $10.55 billion and net income at $2.36 billion for the year. The company also made significant investments in research and development, evidenced by increased R&D expenses and the strategic acquisition of Tularik Inc. for approximately $1.5 billion. However, the company also faced evolving regulatory landscapes, particularly with the Medicare Modernization Act (MMA) potentially impacting future reimbursement rates, and ongoing legal proceedings related to patent and pricing practices, which Amgen believes will not materially affect its financial statements. The company also highlighted its strong liquidity position with substantial cash reserves.

Amgen Inc. reported strong financial performance in 2003, driven by significant growth in its key products, particularly Aranesp®, Neulasta®, and ENBREL®. Total revenues surged by 58% to $7.87 billion, largely due to the successful integration of Immunex and robust demand for its new biologics. The company's strategic focus on expanding its product pipeline and manufacturing capabilities is evident in its substantial capital expenditures, including investments in new manufacturing plants in Rhode Island and Puerto Rico. While Amgen faces ongoing legal proceedings and investigations related to drug pricing and patent disputes, management stated that these are not expected to have a material adverse effect on its financial statements. The company maintains a strong liquidity position and continues to invest in research and development to fuel future growth.

Amgen Inc.'s 2002 10-K filing highlights a year of significant growth and strategic expansion, largely driven by the transformative acquisition of Immunex Corporation in July 2002. This acquisition significantly bolstered Amgen's product portfolio and pipeline, particularly in the immunology and inflammation areas, with the addition of ENBREL®. Total revenues increased by 42% to $5.52 billion, fueled by strong performance from key products like Neulasta™, Aranesp®, and EPOGEN®, alongside the initial contribution from ENBREL®. Despite a substantial net loss of $1.39 billion, primarily due to a non-cash write-off of $2.99 billion for acquired in-process research and development related to the Immunex deal, the company's operational performance, excluding this one-time charge, demonstrated robust growth. Amgen maintained a strong financial position with substantial cash reserves, supporting ongoing investments in research and development and strategic initiatives.

Amgen Inc. reported strong performance in its 2001 fiscal year, driven by its key biopharmaceutical products. Total revenues reached $4.016 billion, a significant increase driven by product sales, which grew by 10% to $3.511 billion. This growth was primarily fueled by EPOGEN® and its newer counterpart Aranesp™, which saw combined sales rise by 10% to $2.150 billion, bolstered by new market approvals for Aranesp™ and increased demand for EPOGEN®. NEUPOGEN®, another cornerstone product, also demonstrated robust growth, with worldwide sales increasing by 10% to $1.346 billion due to increased demand and pricing. The company is actively investing in research and development, with R&D expenses at $865 million, focusing on therapeutic areas such as nephrology, cancer, inflammation, and neurology. A major strategic development was the announcement of a definitive agreement to acquire Immunex Corporation for an estimated $17.6 billion, signaling a significant move to expand its product portfolio and market presence.

Amgen Inc.'s 1998 10-K filing, reported on March 15, 1999, details a year of significant operational and financial activity for the biotechnology company. While specific financial figures for revenue, net income, and key product sales are not directly available in the provided snippet, the filing indicates a company focused on its core business of developing and commercializing human therapeutics. Investors would be keen to understand the company's product pipeline, regulatory approvals, manufacturing capabilities, and its competitive landscape within the burgeoning biotechnology sector. Given the filing's date, the focus is likely on the performance of established products and the progression of late-stage clinical trials. Amgen's strategic priorities would revolve around maximizing the value of its existing portfolio, managing intellectual property, and investing in research and development to secure future growth. The overall tone would be one of continued innovation and expansion in the biopharmaceutical market, positioning Amgen as a key player in addressing unmet medical needs.

Amgen Inc.'s 1997 10-K filing, filed in May 1998, represents an amendment, indicating a potential update or correction to previously submitted information for the fiscal year ending December 30, 1997. As a leading biotechnology company, investors would be keenly interested in the company's financial health, product pipeline, regulatory approvals, and overall market position. This filing would provide insights into Amgen's revenue streams, operating expenses, profitability, and any significant developments that could impact its future performance. Key areas of focus for investors would include the commercial success of its existing products, such as Epogen and Neupogen, and any progress in the development and approval of new therapeutic agents. The competitive landscape within the biotechnology sector, potential patent expirations, and Amgen's strategic initiatives, including research and development investments and potential mergers or acquisitions, would also be critical factors influencing investor sentiment and valuation. This amended filing likely offers a more refined view of these crucial elements for the 1997 fiscal year.

Amgen Inc.'s 1997 Annual Report (10-K), filed in March 1998, reflects a company firmly established in the biotechnology sector, focusing on the development, manufacture, and marketing of human therapeutics. The report details significant achievements and ongoing strategies aimed at expanding its product portfolio and therapeutic reach. Investors can infer a company driven by innovation and a commitment to addressing unmet medical needs, leveraging its scientific expertise to bring novel treatments to market. Key to Amgen's strategy highlighted in this period is its reliance on blockbuster drugs and the continuous pursuit of new molecular entities. The company's financial health is underpinned by strong product sales, which fuel further research and development investments, positioning it for sustained growth. Amgen's operational focus includes efficient manufacturing and global commercialization efforts to maximize the impact and accessibility of its innovative medicines.

Amgen Inc.'s 1996 10-K filing, reported in March 1997, highlights the company's performance and strategic positioning as a leading biotechnology firm. The report likely details advancements in its key therapeutic areas, including oncology, inflammation, and bone diseases, driven by its proprietary technologies and a robust product pipeline. Investors would have focused on the commercial success of established products and the progress of pipeline candidates through clinical trials, as these are critical drivers of future revenue and profitability in the dynamic biotechnology sector. The filing also would have provided insights into Amgen's financial health, including revenue growth, profitability, and investments in research and development (R&D). The company's commitment to innovation and its ability to navigate the complex regulatory landscape are crucial for sustained growth. Investors would be keen to understand the company's outlook, potential market opportunities, and any competitive challenges or strategic partnerships that could impact its long-term value.

Amgen Inc. (AMGN) filed its 10-K for the fiscal year ending December 30, 1995, on March 28, 1996. While the provided text is primarily a directory listing of the filing's components rather than the full report, it indicates Amgen's adherence to SEC reporting requirements during this period. Investors reviewing this filing would typically look for detailed financial statements, management's discussion and analysis of financial condition and results of operations, and risk factors. Given the 1995 fiscal year, the filing would provide a retrospective view of Amgen's performance and strategic positioning. Key areas of interest for investors would include revenue growth, profitability, key product performance (such as Epogen and Neupogen), research and development pipeline progress, and any significant collaborations or acquisitions. Understanding the company's financial health and future growth prospects as presented in this 10-K would be crucial for investment decisions.

Amgen Inc.'s 1994 10-K filing, released on March 30, 1995, reflects a company in a significant growth phase, characterized by advancements in its biotechnology operations and product pipeline. The report details the company's financial performance and strategic initiatives, highlighting its commitment to research and development as a core driver of value. Investors can expect to find information regarding the company's key therapeutic areas, its expanding manufacturing capabilities, and its efforts to bring innovative treatments to market. The filing serves as a crucial snapshot of Amgen's position in the burgeoning biotechnology sector at the time. It underscores the company's focus on leveraging scientific innovation to address unmet medical needs, positioning itself for sustained growth and leadership. Investors should pay close attention to the segments discussing product development, regulatory approvals, and commercialization strategies as indicators of future revenue potential and market impact.